Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)
Open
National Institutes of Health is offering grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications close on January 28, 2028.
From the official notice on Grants.gov, last changed June 17, 2025. Checked October 31, 2026.
- Award ceilingnot stated
- Award floornot stated
- Expected awardsnot stated
- Total fundingnot stated
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | June 17, 2025 |
|---|---|
| Deadline | January 28, 2028 |
| Archived by Grants.gov | March 4, 2028 |
Add the deadline to your calendar
Who can apply
This opportunity is open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
The purpose of this announcement is to encourage investigators to pursue translational activities and clinical feasibility studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent clinical feasibility study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This FOA is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress. Participants in Blueprint MedTech receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants to receive assistance with specialty areas including regulatory, reimbursement, intellectual property, commercialization, and strategic partnerships. Participants can also augment their project with NIH contract research organizations that specialize in large animal testing, sterilization testing, biocompatibility assessment, manufacturing, and medical monitoring. Individuals, institutions, or businesses developing their own devices or that already have established collaborations with device manufacturers are welcome to apply directly to this NOFO or any of the companion opportunities. For more information see BP MedTech website.
How to apply
- Read the full notice and attachments on Grants.gov and the agency's announcement. The notice is the official source for deadlines and requirements.
- Make sure your organization has an active SAM.gov registration and Unique Entity ID; registration can take several weeks.
- Register on Grants.gov and submit through Workspace before the deadline and time given in the notice. Our application guide walks through each step.
Questions go to National Institutes of Health, grantsinfo@nih.gov, 301-402-2541.
Questions people ask
Who can apply for Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)?
National Institutes of Health accepts applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Blueprint MedTech Translator (UG3/UH3 - Clinical Trial Optional)?
Closes January 28, 2028 (454 days left). Confirm the date and time in the official notice on Grants.gov.
Similar open grants
- Continuation of the Collaborative Islet Transplantation Registry (U01 Clinical Trial Not allowed)
- BRAIN Initiative Cell Atlas Network (BICAN): Coordinating Unit for Biostatistics, Informatics, and Engagement (CUBIE)
- Centers without Walls for mechanisms of neurodegeneration in Alzheimer’s disease-related dementias (ADRD)
- Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)
- Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE, RP1 Clinical Trial Not Allowed)
- Exposomic Contributions to ADRD Pathology and Resilience